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Treatment of wild type vaccinia virus infected cells with the anti-poxviral drug isatin-β-thiosemicarbazone (IBT) induces the viral
postreplicative transcription apparatus to synthesize longer-than-normal mRNAs through an unknown mechanism. Previous studies have shown
that virus mutants resistant to or dependent on IBT affect genes involved in control of viral postreplicative transcription elongation. This study was
initiated in order to identify additional viral genes involved in control of vaccinia postreplicative transcription elongation. Eight independent,
spontaneous IBT resistant mutants of vaccinia virus were isolated. Marker rescue experiments mapped two mutants to gene G2R, which encodes a
previously characterized postreplicative gene positive transcription elongation factor. Three mutants mapped to the largest subunit of the viral
RNA polymerase, rpo147, the product of gene J6R. One mutant contained missense mutations in both G2R and A24R (rpo132, the second largest
subunit of the RNA polymerase). Two mutants could not be mapped, however sequence analysis demonstrated that neither of these mutants
contained mutations in previously identified IBT resistance or dependence genes. Phenotypic and biochemical analysis of the mutants suggests
that they possess defects in transcription elongation that compensate for the elongation enhancing effects of IBT. The results implicate the largest
subunit of the RNA polymerase (rpo147) in the control of elongation, and suggest that there exist additional gene products which mediate
intermediate and late transcription elongation in vaccinia virus.
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Because poxviruses are double-stranded DNA-containing
viruses that replicate exclusively in the cytoplasm of infected
cells, they must encode enzymes required for viral transcription
and genome replication. This task is facilitated by the large
coding capacity of poxviral genomes. The archetypal poxvirus,
vaccinia virus, possesses a 195 kbp genome and has long been⁎ Corresponding author.
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doi:10.1016/j.virol.2007.02.005used as a model system for studying DNA replication and
transcription (Moss, 2001).
Transcription in vaccinia virus is carried out by a virus-coded
multi-subunit DNA-dependent RNA polymerase that shares
homology with both prokaryotic and eukaryotic enzymes
(Broyles and Moss, 1986). There are two forms of the vaccinia
RNA polymerase: a nine-subunit form that transcribes viral
early genes, and an eight subunit form that lacks an early
polymerase-specific subunit (RAP94; gene H4L) but is
otherwise identical to the early form (Ahn and Moss, 1992;
Deng and Shuman, 1994; reviewed in Condit and Niles, 2002;
Broyles, 2003). The eight-subunit polymerase functions solely
after DNA replication to specifically transcribe genes of the
intermediate and late (collectively termed postreplicative)
classes (Wright and Coroneos, 1995).
Control of postreplicative gene transcription elongation and
termination differs fundamentally from that of early genes
(reviewed in Condit and Niles, 2002). Early gene termination
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UUUUUNU, is recognized with high efficiency, and early
transcripts are therefore homogeneous in length (Yuen and
Moss, 1987). By contrast, transcripts produced from any given
postreplicative gene are heterogeneous in length (Cooper et al.,
1981; Mahr and Roberts, 1984). Termination of postreplicative
genes is not responsive to the early gene cis-acting element
(Condit et al., 1996a); the postreplicative transcription termina-
tion cis acting sequence, if it exists, must therefore be either
simple or degenerate, and must function inefficiently. Viral
factors required for early termination are relatively well
characterized and include RAP94 (gene H4L), NPH I (gene
D11L) and VTF (genes D1R and D12L) (Shuman et al., 1987;
Christen et al., 1998; Deng and Shuman, 1998; Mohamed and
Niles, 2000). Elongation and termination of postreplicative
gene transcription is influenced by a set of factors distinct from
those which effect early termination. These factors include the
negative transcription elongation factor A18, and the positive
transcription elongation factors G2 and J3, described below.
Factors affecting intermediate and late transcription elonga-
tion or termination were originally identified by a phenotypic
analysis of a collection of temperature-sensitive vaccinia virus
mutants (Condit and Motyczka, 1981; Condit et al., 1983).
Mutants Cts4, Cts22, and Cts23 exhibited a phenotype that
featured sudden degradation of cellular and viral RNA late
during infection (Pacha and Condit, 1985). These mutants
mapped to the A18R gene (Pacha et al., 1990), which was later
shown to produce an essential transcript release factor with
DNA helicase and DNA-dependent ATPase activities (Bayliss
and Condit, 1995; Simpson and Condit, 1995; Lackner and
Condit, 2000). Due to the absence of the transcript release factor
activity, A18R mutants produce postreplicative mRNAs of
increased length. Some of these long mRNA molecules have
large stretches of complementarity to one another since they are
produced from converging transcriptional promoters. This
complementarity allows the formation of long dsRNA mole-
cules. The increase in cellular dsRNA concentration in turn
activates the cellular 2–5 A antiviral pathway and ultimately
leads to activation of the latent ribonuclease L which degrades
both viral and cellular RNA (Pacha and Condit, 1985; Cohrs et
al., 1989; Bayliss and Condit, 1993; Xiang et al., 1998).
The phenotype of mutants mapping to genes G2R or J3R is
the converse of the A18R mutant phenotype. G2R and J3R
mutants produce late mRNAs that are truncated from their 3′
ends and are therefore reduced in size relative to wild type
mRNAs (Black and Condit, 1996; Latner et al., 2000). Thus, the
truncated mRNAs produced by G2R and J3R mutants are long
enough to encode the small late proteins but are too short to
encode large late proteins, which are synthesized in correspond-
ingly reduced amounts. The phenotype of these mutants
suggested that G2 and J3 each function as postreplicative
gene positive transcription elongation factors. Consistent with
the opposing phenotypes of A18R mutants compared with G2R
or J3R mutants, extragenic suppression of a temperature
sensitive allele of A18R can be achieved by null mutation of
G2R or J3R (Condit et al., 1996b; Latner et al., 2000). While
these genetic studies suggest that G2 and J3 function as trans-cription elongation factors, to date they have no biochemically
defined roles in elongation and no detectable sequence
homology to non-poxviral elongation factors that would
provide clues about their functions. J3 does perform two duties
besides its role in transcription elongation: it is the (nucleoside-
2′-O-)-methyltransferase for the mRNA 5′ cap maturation and
the stimulatory factor for the vaccinia-encoded poly(A) poly-
merase, E1 (Gershon et al., 1991; Schnierle et al., 1992). The
transcription elongation factor activity of J3 is independent of
the methyltransferase and poly(A) polymerase stimulatory
activities (Latner et al., 2002). G2 has no other known activities
but has been shown to bind the H5 protein, a stimulatory factor
for late transcription (Kovacs and Moss, 1996; Black et al.,
1998; McCraith et al., 2000).
The treatment of wild type infected cells with the anti-
poxviral drug isatin-β-thiosemicarbazone (IBT) induces the
postreplicative transcription apparatus to synthesize longer-
than-normal mRNAs through an unknown mechanism (Xiang,
1998). This mimics the phenotype observed during infection
with an A18R mutant. Just as mutation of A18R leads to the
activation of the cellular 2–5 A pathway, infection in the
presence of IBT also induces the 2–5 A pathway and triggers
the degradation of both viral and cellular RNA (Pacha and
Condit, 1985; Cohrs et al., 1989; Bayliss and Condit, 1993). For
this reason, we hypothesize that IBT functions to promote
transcription elongation or inhibit transcription termination. It
follows then that mutants capable of growth in the presence of
IBT might leverage one of at least two potential mechanisms. A
structural change in the IBT binding site could prevent the drug
from binding its target. Alternatively, an impairment in
transcription elongation might compensate for the elongation-
promoting effects of the drug.
Several mutants have been isolated that are resistant to or
dependent upon IBT for growth (Katz et al., 1973a,b; Meis and
Condit, 1991). IBT-dependent mutants mapping to G2R and
J3R have been shown to produce intermediate and late
transcripts in vivo that are shorter than the wild type length
(Black and Condit, 1996; Latner et al., 2000, 2002; Xiang et al.,
2000). In addition, an IBT-resistant mutant mapping to A24R,
the gene that encodes the second-largest subunit of the RNA
polymerase (rpo132), was identified and characterized as
elongation defective in vitro (Condit et al., 1991; Prins et al.,
2004). Thus, the compensatory model of defective transcription
elongation appears to accurately describe several IBT-resistant
and IBT-dependent mutants. While the precise mechanism of
action and target of IBT are unknown, IBT has clearly been
established as a valuable tool that can be used to select for
mutants in factors affecting transcription elongation.
In order to further characterize the proteins which mediate
intermediate and late vaccinia gene transcription elongation, we
have isolated and characterized a collection of eight indepen-
dently derived, spontaneous IBT-resistant mutants. These
mutants display varying transcription elongation phenotypes,
implicate the largest subunit of the RNA polymerase (rpo147) in
the control of elongation, and suggest that there exist additional
gene products which mediate intermediate and late transcription
elongation in vaccinia virus.
Table 1
Mutant genotypes
Virus Gene DNAa Protein b
DL1-3 J6R C1604T A535V
DL2-4 G2R, A24R G2R: G475A;
A24R: A3227G
G2:A159T;
A24R: D1076G
DL3-2 J6R C863A S288Y
DL4-10 Unknown Unknown Unknown
DL5-7 G2R G290T G97V
DL7-3 Unknown Unknown Unknown
DL8-1 G2R Δ549 fs 184, term 187
DL10-7 J6R C1604T A535V
a Δ=single base deletion.
b fs= frameshift; term=translation termination codon.
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Plaque phenotypes
Eight independently derived spontaneous IBT-resistant
mutants of vaccinia virus were isolated as described in Materials
and methods. In order to visualize the ability of the mutants to
grow relative to one another and to wild type virus in both the
absence and presence of IBT, a plaque assay was performed.
Fig. 1 shows appropriate dilutions from a 37 °C plaque assay for
each virus. The wild type virus is IBT-sensitive and forms large
plaques only in the absence of IBT. Relative to wild type, many
of the IBT-resistant mutants display a small plaque phenotype in
the absence of drug. For DL1-3 and DL10-7, plaque size is not
influenced by the presence or absence of drug. Each of the other
viruses forms larger plaques in the absence of IBT than in the
presence of IBT, though the size of those plaques varies by
virus. In the case of DL5-7 and DL8-1, plaques formed in the
absence of drug are equivalent in size to wild type plaques.
Thus, the IBT-resistant viruses represent a spectrum of plaque
phenotypes and display drug resistance to varying degrees.
Genetic mapping
To determine the specific mutation responsible for the IBT-
resistance phenotype of each mutant, we used a combination
of marker rescue mapping and DNA sequencing. Because ofFig. 1. Plaque assay of IBT-resistant mutants in the presence and absence of IBT. The
to staining with crystal violet. (For interpretation of the references to colour in thisthe high likelihood that a subset of these mutants would map
to genes previously implicated in IBT-resistance or control of
elongation, we sequenced the A18R, G2R, J3R, and A24R
allele in each mutant (Table 1). None of the mutants
contained mutations in genes A18R or J3R. Of the eight
mutants, three contained mutations in G2R (DL2-4, DL5-7,
and DL8-1), one of which (DL2-4) also contained a mutation
in A24R. The five remaining mutants (DL1-3, DL3-2, DL4-
10, DL7-3 and DL10-7) were of particular interest since they
carry wild type alleles of A18R, G2R, J3R, and A24R,
implying that the drug-resistance phenotype of these mutants
maps to one or more novel IBT-resistance genes.dishes were incubated at 37 °C for 6 days in the presence or absence of IBT prior
figure legend, the reader is referred to the web version of this article.)
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the IBT-resistance phenotype of the G2R mutants and G2R/
A24R double mutant does in fact map to these genes. BSC40
cells were first infected with a temperature sensitive helper virus
(Dts38), then co-transfected with wild type genomic DNA and a
series of PCR products amplified from each mutant. The
infected, co-transfected dishes were incubated at 37 °C (non-
permissive temperature for Dts38) in the presence of IBT in
order to select for IBT-resistant recombinants resulting from the
rescue (seeMaterials andmethods). Negative controls in this and
all other marker rescue experiments presented include unin-
fected cells, cells infected with the Dts38 helper virus but not
transfected, and cells infected with Dts38 and transfected with
wild type genomic DNA but no PCR product. A signal overFig. 2. Initial marker rescue mapping of DL1-3. (A) Primer pairs used to construct PC
shown as bars above the region they amplify on aHindIII restriction map of the vaccin
numbers shown here are used throughout our study. (B) Confluent dishes of BSC40 c
genomic DNA and the indicated PCR product. After a 4 day incubation at 37 °C in the
references to colour in this figure legend, the reader is referred to the web version obackground was observed for each G2R mutant except DL2-4,
theG2R/A24R double mutant (data not shown). Attempts to map
the IBT-resistance phenotype of this virus to the G2R or A24R
genes individually or collectively have been unsuccessful.
Because initial sequence analysis of DL1-3, DL3-2, DL4-10,
DL7-3 and DL10-7 revealed no mutations in A18R, G2R, J3R,
and A24R, mapping of these mutants was attempted using
overlapping 5 kbp PCR products generated from the genomes of
each mutant (Fig. 2A). This set of 40 primer pairs can be used to
amplify virtually the entire vaccinia virus genome (Luttge and
Moyer, 2005).
The central core region of the vaccinia genome is highly
conserved throughout the poxvirus family and contains the bulk
of the essential genes. Thus, initial rescues were attempted withR products for marker rescue. Products amplified using a library of primers are
ia virus genome. Each product is approximately 5 kb in length. The PCR product
ells were infected with the Dts38 helper virus and co-transfected with wild-type
presence of IBT, dishes were stained with crystal violet. (For interpretation of the
f this article.)
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region. In the first such experiment, PCR products 13 to 27 were
amplified from the DL1-3 genome. When these products were
transfected in a marker rescue experiment, the result showed that
DL1-3 maps to a 5 kbp region containing part of J3R, all of J4R
and J5L, and part of J6R (Fig. 2B, dish “20”). Although it was
known that this mutant did not map to J3R due to prior DNA
sequencing, each of the J3R, J4R, J5L, and J6R open reading
frames was PCR amplified and transfected in a second marker
rescue experiment (Fig. 3). The result showed that DL1-3 maps
to J6R, the gene encoding the largest subunit of the RNA
polymerase.
Mapping of DL3-2 was performed essentially as described
for DL1-3, except that 40, 5 kbp PCR products spanning the
genome were used in the initial round of mapping. Although
DL3-2 did not produce a signal as robust as that seen with DL1-
3, the genome-wide marker rescue indicated that DL3-2 also
mapped to the 5 kbp PCR product containing all or part of genes
J3R, J4R, J5L, and J6R. Fig. 4A shows the positive rescue done
with PCR fragment 20 along with the WT genome control; all
other dishes in this experiment, including the remaining 39 PCR
fragment transfected dishes, were indistinguishable from the
WT genome control. As had been done with DL1-3, genes J3R,
J4R, J5L, and J6R were PCR amplified from the DL3-2
genome and used in a subsequent marker rescue experiment
(Fig. 4B). In this and some other marker rescue experiments, we
noticed a relatively high background of plaques in dishes that
had been infected with helper virus and cotransfected with wild
type genomic DNA and mutant PCR fragments, especially
compared to controls. This background most likely results from
residual mutant genomic DNA that was used as a template for
the PCR reaction and is therefore present in transfections and
can be reactivated by the helper virus. Often this background
can be reduced by repeating the PCR amplification using theFig. 3. Marker rescue mapping of DL1-3 to the J6R gene. Confluent dishes of BSC40
genomic DNA (“WTGenome”) and the indicated PCR product. After a 4 day incubat
and some other experiments, plaques appearing in the control dish (“WT genome”) pr
resistance alleles present in the wild type virus genomic DNA used in co-transfection
the reader is referred to the web version of this article.)first round of PCR products as templates for a second round of
PCR. Despite the background, the marker rescue experiment
shown in Fig. 4B gave a significantly larger number of plaques
after transfection with the J6R gene DNA fragment compared
with other fragments. This experiment showed that DL3-2, like
DL1-3, mapped to the J6R gene.
Because both DL1-3 and DL3-2 mapped to the J6R gene, the
remaining mutants, DL4-10, DL7-3, and DL10-7, were assayed
to determine if they mapped to J6R as well. First the J6R gene
from each of these three mutants was sequenced. From this it was
determined that the J6R genes of DL4-10 and DL7-3 are wild
type in DNA sequence (Table 1). Combined with the initial
sequencing effort, these data indicate that DL4-10 and DL7-3
must map to a gene other than A18R, G2R, J3R, A24R, and J6R.
Repeated attempts to map each of these mutants have been
unsuccessful (data not shown). On the other hand, DL10-7 was
shown by sequence analysis to contain a mutation in J6R (Table
1). Surprisingly, the genotype of this mutant was identical to that
of DL1-3. Marker rescue analysis confirmed that IBT-resistance
in this mutant did in fact map to its J6R mutation and not any
other gene implicated in IBT-resistance (data not shown).
Genes that gave positive results in marker rescue experiments
were PCR amplified with primers flanking the coding sequence,
and these products were sequenced as described inMaterials and
methods. Results from the sequencing are summarized in Table
1. The sequencing revealed coding mutations in theG2R gene of
DL5-7 and DL8-1 and the J6R gene of DL1-3, DL3-2, and
DL10-7. These results corroborate the marker rescue mapping.
As a final confirmation that the mutations identified in the
marker rescue and sequencing are responsible for the IBT
resistance phenotype of each mutant, the marker rescue
experiments were repeated using an agar overlay so that
rescued viruses could be isolated from individual plaques.
Three plaques were picked from rescues done with each of thecells were infected with the Dts38 helper virus and co-transfected with wild-type
ion at 37 °C in the presence of IBT, dishes were stained with crystal violet. In this
obably represent IBT resistant viruses, most likely arising from spontaneous IBT
experiments. (For interpretation of the references to colour in this figure legend,
Fig. 5. Northern analysis of IBT-resistant mutant RNA. Confluent BSC40 cells
were infected with the indicated virus at m.o.i.=15 in the presence or absence of
IBTand incubated at 37 °C for 9 h. Total cellular RNAwas purified, fractionated
by gel electrophoresis and transferred to a nylon membrane. The membrane was
probed with a riboprobe specific for the intermediate K2L gene and exposed to
film. The virus used for infection is indicated at the top of the autoradiogram.
The presence of absence of IBT in the infection is indicated with a “+” or a “−” at
the top of the autoradiogram. Size markers are indicated at the left of the
autoradiagram, in kb.
Fig. 4. Marker rescue mapping of DL3-2 to the J6R gene. Confluent dishes of BSC40 cells were infected with the Dts38 helper virus and co-transfected with wild-
type genomic DNA (“WT Genome”) and the indicated PCR product. After a 4 day incubation at 37 °C in the presence of IBT, dishes were stained with crystal
violet. (A) Initial marker rescue mapping of DL3-2. Shown are the control dish transfected with WT genomic DNA alone (“WT Genome”), and the positive dish co-
transfected with WT genomic DNA and PCR product 20 amplified from the DL3-2 genome (“20”). (B) Marker rescue using gene specific PCR products spanning
PCR fragment 20. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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were picked from a DL10-7 rescue. The viruses in each of these
plaques were grown in the presence of IBT, plaque purified, and
grown again in the presence of IBT to produce a lysate. DNA
was extracted from the lysate and used as a template for PCR.
The PCR amplified G2R or J6R gene was then sequenced, and
in each case the nucleotide change found in the original IBT
resistant mutants was also present in the viruses derived from
those mutants. Interestingly however, one of the DL1-3 derived
viruses possessed a second nucleotide substitution (G1603T) in
addition to the original mutation (C1604T) in J6R, resulting in a
different missense mutation (A535F) relative to what is present
in DL1-3 (A535V).
In vivo analysis of transcription elongation
Because IBT appears to influence transcription elongation,
the in vivo transcription phenotype of the IBT-resistant mutants
was analyzed. Northern blots were performed using probes
specific for the 5′ ends of three vaccinia virus genes in order to
measure the length of transcripts produced from these genes
during infections with the eight IBT-resistant mutants. The
probes used were specific for the intermediate K2L gene (Fig.
5), the highly expressed late A10L gene (not shown), and the
early/late A18R gene (not shown). In each case, 9 h post
325S.G. Cresawn et al. / Virology 363 (2007) 319–332infection (h.p.i.) RNA from cells infected in the presence and
absence of IBT was used. Control RNA samples included
those isolated from mock-infected cells or cells infected with
IBT-sensitive wild type virus, with the IBT-resistant IBTr90
virus (Condit et al., 1991; Prins et al., 2004), or with the IBT-
dependent G2A virus (Meis and Condit, 1991).
Results from the Northern blotting experiments confirmed
the effect of IBT on transcripts produced from IBT-sensitive
(wild type), IBT-resistant (IBTr90), and IBT-dependent (G2A)
viruses (Fig. 5). Regardless of the virus tested, transcription of
theK2L gene produces a population of transcripts that are highly
heterogeneous in length and longer in the presence of IBT than in
its absence. Northern blots of RNA from wild type infections
done in the absence of IBT show the normal distribution of K2L
transcripts. Wild type transcripts produced in the presence of
IBT reach a length sufficient to trigger their degradation via the
2–5 A pathway (Pacha and Condit, 1985; Cohrs et al., 1989;
Bayliss and Condit, 1993; Xiang, 1998). Products of this
degradation are seen as a low molecular weight smear that is
absent from each of the other lanes. In the absence of IBT, the
IBT-resistant mutant IBTr90 synthesizes transcripts that are
apparently similar in length to wild type. In the presence of IBT
however, the mRNA degradation seen with the wild type virus is
not observed in the IBTr90 infection. The IBT dependent mutant
G2A produces only very short transcripts in the absence of IBT,
but G2A transcripts synthesized in the presence of IBT have a
normal size distribution. The phenotype of each of the remaining
IBT-resistant viruses resembles that of IBTr90. Similar experi-
ments conducted with probes specific for the A10L and A18R
genes (data not shown) produced results indistinguishable from
that of K2L. Consistent with the northern analysis, rRNA
visualized by ethidium bromide staining of these same gels
before transfer reveals rRNA breakdown in wild type infections
done in the presence of IBT, while in all other infections rRNA
remained intact. In summary, during infection with each of the
viruses tested, whether IBT sensitive, dependent or resistant,
addition of IBT to the infections resulted in synthesis of longer
transcripts compared to infections done in the absence of drug.
No reproducible differences were observed in size or quantity
of RNAs synthesized in the absence of IBT, however subtle
differences in the average distribution of sizes may exist which
are beyond the sensitivity of these experiments. The size
distribution of mutant RNAs made in the presence of IBT
cannot be legitimately compared to the RNAs made during a
wild type infection in the presence of IBT because of the RNA
breakdown induced during the wild type infection.
In vitro analysis of transcription elongation
An in vitro transcription elongation system was utilized to
complement and extend the analysis of transcripts synthesized
in vivo. Transcription extracts were made from each of the
IBT-resistant viruses (with the exception of DL10-7 because it
has the same genotype as DL1-3) and assayed for their ability to
promote transcription elongation compared to a wild type
extract. The DNA template used in this assay, pG8GU, which
was designed to analyze elongation of the transcriptioncomplexes through an artificial pause site, contains the vaccinia
virus G8R gene intermediate promoter followed by a 37 bp G-
less cassette, then a 40 bp T-less cassette, then a 9 bp poly-T
stretch, and lastly 42 bp of plasmid DNA and is bound to
streptavidin-coated paramagnetic beads (Prins et al., 2004).
During a pulse reaction, virus extracts were incubated with the
DNA template in transcription buffer that included ATP, UTP,
32P-CTP, and 3′-O-MethylGTP. The incorporation of the 3′-O-
MethylGTP at the end of the 37 bp G-less cassette causes
transcriptional arrest and allows the transcription complex to be
isolated on a magnet and washed with buffer to remove
unincorporated nucleotides and proteins. The pulse reaction
produces labeled transcripts of varying lengths due to the
addition of a 30–50 bp poly-A head on vaccinia post-replicative
transcripts (Schwer et al., 1987). Elongation resumes during a
chase phase of the reaction when buffer containing ATP, CTP,
GTP, and varying amounts of UTP is added to the washed
complexes and they are incubated at 30 °C for 5 or 30 min. The
resumption of elongation presumably follows removal of 3′-O-
MethylGTP via an exonuclease mechanism (Hagler and
Shuman, 1993).
Results of the in vitro transcription elongation assay of
DL1-3, a mutant whose IBT resistance maps to the largest
subunit of the vaccinia RNA polymerase, rpo147, are shown
in Fig. 6. For both the wild type and DL1-3 viruses,
transcription elongation in the chase reaction does not
proceed beyond the 9 nt poly-T pause site in the absence
of UTP (Fig. 6A, lanes 2, 10, 19, 27). As UTP levels increase
in the chase reaction, the amount of elongation increases for
each virus, but the wild type virus produces a higher
percentage of full length transcripts than the DL1-3 virus at
UTP levels of 10 μM and above (Figs. 6B, C). Thus, DL1-3
exhibits a transcription elongation defect. Compared to a
previous analysis of IBTr90 (Prins et al., 2004), an IBT-
resistant mutant mapping to rpo132, this transcription
elongation defect appears to be quite severe.
Transcription extracts from DL1-3 infected cells were also
significantly decreased in overall transcription activity com-
pared to wild type extracts; note in Fig. 6 that the autoradiogram
for the DL1-3 transcription assay was exposed 12 times longer
than the wild type assay. The total activity recovered from all of
the mutants varied from 7 fold greater than wild type extracts
(DL2-4) to 30 fold less than the wild type extract (DL1-3);
however these variations showed no clear correlation with any
other aspect of the mutant phenotype.
The results of transcription elongation analysis of DL3-2
infected cell extracts are presented in Fig. 7. Again, both the
wild type and DL3-2 viruses do not transcribe beyond the poly-
T site if UTP is not included in the chase reaction (Fig. 7A, lanes
2, 10, 19, 27), however the wild type virus produces a higher
percentage of full-length transcripts than the DL3-2 virus as
UTP levels are increased in the chase reaction (Figs. 7B, C). The
elongation defect of the DL3-2 mutant does not appear to be as
severe as that of the DL1-3 or of IBTr90 mutants.
Transcription elongation assays done with extracts from the
remaining mutants assayed, specifically DL2-4, DL4-10, DL5-
7, DL7-3, and DL8-1, showed no differences in transcription
Fig. 6. In vitro transcription elongation assay of DL1-3. Extracts from wild type and DL1-3 infected cells were prepared and assayed for transcription elongation in
vitro as described in Materials and methods. (A) An autoradiogram showing the amount of readthrough transcription as a function of time and UTP concentration.
Source of extract, time of chase and UTP concentration are indicated at the top of the autoradiogram. Transcription products are indicated to the left of the
autoradiogram. “Pulse” indicates the transcript arrested at the end of the 37 nt G-less cassette. “Pause” indicates the transcript paused at the poly-T sequence. “Full-
length” indicates transcript resulting from transcription to the end of the DNA template. Size markers are indicated to the right of the autoradiogram. The
autoradiogram of transcription with wild type extracts was exposed for 17 h. The autoradiogram of transcription with DL1-3 extracts was exposed for 9 days. (B)
Comparative quantification of results from a 5 min chase. Gels were exposed on a phosphorimager, and percent readthrough was calculated as the amount of full length
transcript divided by the total transcription (equal to the sum of the full length transcript plus the paused transcript) and multiplied by 100. (C) Comparative
quantification of results from a 30 min chase.
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the case of the G2R mutants, DL5-7 and DL8-1, this result was
not surprising since in this assay even the G2R null mutant,
G2A, is indistinguishable from wild type (C. Prins, unpublished
data). In fact, in our experience this transcription elongation
assay is specific for mutation of the RNA polymerase and thus
fails to measure defects in elongation caused by mutation of
elongation factors. Therefore, the lack of an elongation defect in
DL2-4, DL4-10, and DL7-3 extracts implies that the IBT-
resistance loci in these mutants affect proteins other than the
RNA polymerase.
Discussion
The goal of the work presented here was to explore the
network of factors that collectively control the length of
vaccinia virus intermediate and late mRNA transcripts. This
study and those that preceded it took advantage of spontaneousIBT-resistant or IBT-dependent vaccinia virus mutants. Muta-
tions in these viruses have generally affected one of two
categories of genes: RNA polymerase subunits and elongation
factors. The former category was comprised of a single mutant,
IBTr90, that mapped to the second-largest subunit of the RNA
polymerase, rpo132 (Condit et al., 1991; Prins et al., 2004). The
latter category consisted of a number of mutants mapping to the
elongation factors J3 and G2 (Meis and Condit, 1991; Black and
Condit, 1996; Latner et al., 2000). In this study, we isolated and
mapped additional spontaneous IBT-resistant mutants in an
attempt to identify novel factors that may be involved in
controlling transcription elongation. New elongation-defective
alleles of G2R were identified and characterized, and for the
first time IBT-resistance was mapped to the gene encoding the
largest RNA polymerase subunit, rpo147. In addition, two IBT-
resistant mutants (DL4-10 and DL7-3) were isolated which,
although they remain unmapped, do not affect any previously
identified elongation factors, implying that additional vaccinia
Fig. 7. In vitro transcription elongation assay of DL3-2. Extracts from wild type and DL3-2 infected cells were prepared and assayed for transcription elongation in
vitro as described in Materials and methods. (A) An autoradiogram showing the amount of readthrough transcription as a function of time and UTP concentration. Both
the wild type and the DL3-2 autoradiograms were exposed for 17 h. (B and C) Comparative quantification of results from a 5 min chase and a 30 min chase. See legend
to Fig. 6 for details.
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elongation.
Several details of the genetic analysis presented here are
noteworthy. First, the A535V IBT-resistance allele of the J6R
gene was recovered in two independently isolated IBT resistant
mutants. The methods used for isolation of the mutants exclude
the possibility that these mutants are sibs. This finding suggests
that the A535 residue is particularly sensitive to selective
pressure for altered RNA polymerase elongation properties.
Second, one of three viruses isolated after rescue of wild type
virus to IBT resistance using the A535V J6R allele possessed a
second nucleotide substitution (G1603T) in addition to the
original mutation (C1604T) in J6R, resulting in a different
missense mutation (A535F) relative to that which is present in
DL1-3 (A535V). The most likely explanation for this observa-
tion is that the rescue resulted initially in the incorporation of
the A535V J6R allele, and that the secondary mutation to the
A535F allele arose spontaneously during amplification of the
rescued virus under selection in the presence of IBT. In any
event, this observation further emphasizes the sensitivity of the
A535 residue to selection for elongation phenotypes. Third, theG2R allele identified in DL8-1 is a frameshift mutation which
truncates the 220 amino acid G2 protein to 186 amino acids,
where the C-terminal three amino acids are mutant owing to the
frameshift at codon 184. Null mutation of the G2R gene results
in IBT dependence (Meis and Condit, 1991). Mutation of G2R
to IBT resistance probably represents G2 function that is
crippled but not absent; the IBT resistance phenotype thus
represents an intermediate condition midway between the wild
type sensitive phenotype and the null mutant dependent
phenotype. The DL8-1 phenotype thus implies that the C-
terminal amino acids of the G2 protein contribute to but are not
absolutely essential for full G2 function.
An analysis of transcript lengths in vivo implies a
transcription elongation defect for each of the IBT-resistant
mutants described here. As discussed previously, two models
that can account for IBT-resistance include one in which
mutation of the IBT binding site on its target prevents the IBT-
target interaction and another in which a deleterious mutation of
the transcription machinery compensates for the ability of IBT
to promote transcription elongation. The existence of a
compensatory deleterious mutation of the transcription
328 S.G. Cresawn et al. / Virology 363 (2007) 319–332machinery would theoretically be revealed in Northern blots as
transcripts that are shorter than the corresponding wild type
transcripts synthesized in the presence or absence of IBT
(excluding degradation induced by IBT during a wild type
infection). However we have found that testing the compensa-
tory model directly in vivo is made difficult by the extreme
heterogeneity of transcript sizes produced from any tested gene.
This compromises the ability to resolve any differences in
transcript length when comparing the IBT-sensitive wild type
virus and the IBT-resistant mutants. In fact, close inspection of
the data in Fig. 5 suggests that the K2L transcripts synthesized
during each of the mutant infections are on average shorter than
the wild type transcripts; however the differences are small and
not reproducibly convincing on repeated experiments with three
different gene specific probes. Nevertheless, the absence of
degradation products in the IBT-resistant mutant infections
done in the presence of IBT implies that these transcripts are
shorter than those produced during a wild type infection in the
presence of IBT, where degradation products are observed.
Also, since IBT exerts an effect on the length of transcripts
produced by each of the IBT-resistant mutants, the drug binding
site of its target likely remains intact, arguing against a drug
binding deficiency model. Lastly, the observation of an
elongation defect in vitro for mutants DL1-3 and DL3-2
supports the compensatory mutation model for the J6R RNA
polymerase mutants.
Characterization of the J6R mutants revealed that they are
defective in an in vitro transcription elongation assay at
intermediate concentrations of UTP relative to wild type virus.
As with IBTr90, extracts made from either DL1-3 and DL3-2
infections exhibit in an increased ratio of paused to full-length
transcripts in vitro. Furthermore, the extent of the defect isFig. 8. Structural modeling of DL1-3 and DL3-2. A model of the vaccinia rpo
structure of S. cerevisiae RNA polymerase II subunit rpb1. Yeast RNA polymera
on the structure of the elongating yeast RNA polymerase. (A) Side (cutaway) view
is in blue, the nontemplate DNA strand is in green, and the RNA is in red. Addi
the yeast RNA polymerase II looking down the pore to the active site of the en
Colors indicate the following: RNA, red; DNA, blue; active site, purple; DL1-3
(2001).greatest in DL1-3 and mildest in DL3-2, with IBTr90 falling in
between (these studies and Prins et al., 2004). In an attempt to
gain mechanistic understanding into the effects of these
mutations, we have used homology modeling to identify
residues in the yeast RNA polymerase that are equivalent to
the residues mutated in each of the vaccinia mutants described
here (Fig. 8). Specifically, the A535 residue that is affected in
DL1-3 and DL10-7 corresponds to amino acid I608 in the rpb1
subunit of the yeast RNA polymerase, and the S228 residue that
is affected in DL3-2 corresponds to amino acid T351 in the rpb1
subunit of the yeast RNA polymerase. Thus according to the
model, the S288Ymutation in DL3-2 is closely positioned to the
active site of the RNA polymerase, with its side chain very near
one of the three universally conserved aspartate residues (D401
in rpo147, D485 in rpb1) that coordinates the active site Mg2+
ion (Zaychikov et al., 1996; Cramer et al., 2001). The potential
for a mutation at this position to interfere with catalysis is readily
evident. The substitution of a tyrosine for a serine presents a
large R group that might, for example, interfere with the
coordination of the active site Mg2+, impose steric constraints
on the free passage of NTPs to the active site, or diminish the
capacity of the polymerase to recover from pausing via its
intrinsic endoribonuclease activity. Modeling of the A535V
mutation found in both DL1-3 and DL10-7 suggests that the
substituted residue is surface-exposed and within a domain of
the polymerase known as pore 1 (Batada et al., 2004). This pore
is critical to the functioning of the polymerase, as it is thought to
serve as an entry port through which NTPs gain access to the
active site and an exit port through which the 3′ end of the
nascent RNA is extruded during retrograde movement of the
polymerase at pause or arrest sites (Fu et al., 1999; Cramer et al.,
2000). Also, in both prokaryotic and eukaryotic systems, the147 (gene J6R) subunit was constructed based on homology to the known
se residues homologous to the mutant vaccinia alleles were then highlighted
of the RNA polymerase II transcribing complex. The template DNA strand
tional structural features of the enzyme are indicated. (B) A close up view of
zyme, with residues homologous to the DL1-3 and DL3-2 alleles indicated.
(yeast I608), orange; DL3-2 (yeast T351), yellow. Panel A is from Klug
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elongation properties of the polymerase itself (Kettenberger et
al., 2003; Opalka et al., 2003). The GreA and GreB factors and
their eukaryotic functional homolog TFIIS are two examples of
proteins that interact via pore 1 to affect transcription elongation.
These enzymes stimulate the endoribonucleolytic cleavage
activity of RNA polymerase in response to RNA polymerase
backtracking at arrest sites (Reines et al., 1993; Toulme et al.,
2000). This activity cleaves the extruded 3′ end of RNA that is
no longer aligned with the active center of the enzyme, resulting
in the formation of a new 3′ end that is appropriately positioned
as a substrate for further transcription elongation. Although no
cleavage stimulatory factors are known to interact with the
vaccinia polymerase, the polymerase itself has been demon-
strated to possess this endoribonuclease activity (Hagler and
Shuman, 1993). Furthermore, the RNA polymerase subunit
rpo30 bears sequence similarity to TFIIS, and extra-molar rpo30
may well serve the role of stimulatory factor (Ahn et al., 1990).
Despite nearly 50 years of research concerning the
antipoxviral effects of IBT, the target of the drug remains
unknown. The specificity of the drug combined with the
existence of both dependent and resistant viral mutants argues
strongly for a viral target. The striking similarity of phenotype
between an A18R viral mutant and the effects of IBT on a wild
type virus infection suggests that the most likely target of the
drug would be the A18 protein (Pacha and Condit, 1985;
Bayliss and Condit, 1993), however none of the nearly 20 IBT
sensitive and IBT resistant mutants isolated to date map to the
A18R gene. IBT has no detectable effect on either A18 or the
vaccinia RNA polymerase in vitro (C. Prins and R.C. Condit,
unpublished observations), though it is possible that the drug is
activated through some unknown modification in vivo, and thus
the “prodrug”would be inactive in vitro. The entire catalogue of
IBT sensitive and resistant mutants to date comprise alleles in
the elongation factors G2 and J3, the RNA polymerase subunits
rpo147 (J6) and rpo132 (A24), and at least one other
unidentified gene. All of these mutants behave like compensa-
tory mutants; no candidate drug binding mutants have been
identified. Based on the number and character of the mutants
isolated we feel that the most likely target for the drug is the
RNA polymerase, however direct proof in support of this
conclusion is currently lacking.
In summary, this work extends the collection of vaccinia
virus mutants that can be used to study intermediate and late
transcription. Genetic mapping of these mutants indicates that
the collection of virus genes that can be mutated to produce IBT
resistance continues to grow and now contains J6R, the gene
encoding rpo147. Furthermore, a comparison of these mutants
to the IBT-sensitive wild type virus, the IBT-resistant IBTr90
mutant, and the IBT-dependent G2A mutant indicates that they
are defective in intermediate/late transcription elongation. Also,
homology modeling of the rpo147 mutants suggests possibi-
lities for the mechanisms underlying those defects and provides
the basis for further experimentation. Lastly, the existence of the
unmapped DL4-10 and DL7-3 mutants implies that additional
genes exist which affect transcription elongation of postrepli-
cative vaccinia genes.Materials and methods
Cells and viruses
Methods used for the propagation of the African green
monkey kidney cell line BSC40, growth of vaccinia virus
stocks, and plaque assays were performed as described
previously (Condit and Motyczka, 1981; Condit et al., 1983).
The human lung carcinoma cell line, A549, was propagated as
previously described (Prins et al., 2004). Vaccinia virus strain
WR was used except where noted. Dts38 is a temperature
sensitive mutant of the IHDW strain of vaccinia affecting the
D5R gene (Lackner et al., 2003). Dts38 does not form plaques
at 37 °C (D'Costa, Lackner and Condit, unpublished observa-
tions). The IBT-resistant mutant IBTr90 contains a Y462H
missense mutation and has a partial defect in intermediate
transcription elongation in vitro (Condit et al., 1991; Prins et al.,
2004). The IBT-dependent mutant G2A has an engineered 10 bp
deletion at codon 90 of the G2R gene that results in a null
phenotype in vivo (Meis and Condit, 1991). Independently
derived, spontaneous IBT-resistant mutants were isolated
exactly as described for IBT-dependent mutants (Latner et al.,
2000). Briefly, 10 well-isolated plaques were picked from a
plaque assay of wild type virus done in the absence of IBT and
these plaques were grown to create stocks. Each of these 10
wild type stocks was then plaque assayed in the presence of
IBT. In each case, a number of plaques were observed due to
spontaneous mutation. Ten of these plaques were picked from
the plaque assay of each of the 10 wild type stocks, for a total of
100 viruses capable of growth in the presence of IBT. These 100
viruses were then plaque assayed in the presence and absence of
IBT to determine whether each was IBT-resistant or IBT-
dependent. Eight IBT-resistant mutants that each originated
from an independent stock of wild type virus were selected for
further study. These viruses were given the names DL1-3, DL2-
4, DL3-2, DL4-10, DL5-7, DL7-3, DL8-1, and DL10-7.
Preparations of IBT were made fresh and used at a final
concentration of 45 μM, as described previously (Pacha and
Condit, 1985).
Polymerase chain reaction
Isolation of DNA for use as a polymerase chain reaction
(PCR) template was done by either of two methods. Total
cellular DNA was purified from monolayers of virus infected
BSC40 cells in 6 cm dishes using the Qiagen DNeasy DNA
isolation kit according to the manufacturer's protocol (Qiagen,
Santa Clarita, CA). Alternatively, virus cores were prepared
from 4×15 cm dishes of infected BSC40 cells (Esposito et al.,
1981), resuspended in 200 ul PBS, and purified using the
Qiagen DNeasy DNA isolation kit.
PCR reactions were optimized for primer and template, but
generally consisted of 400 ng template DNA, 0.32 uM primers
(each), 2 mM MgCl2, 400 μM dNTPs (each), and 2 U Deep
Vent DNA polymerase (New England Biolabs, Beverly, MA).
Products of PCR reactions were purified using Amicon
Centricon spin filters (Millipore, Billerica, MA).
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Sequencing of viral DNAwas performed by PCR amplifying
the region of interest with an appropriate upstream and
downstream primer and submission of the PCR product to the
University of Florida Interdisciplinary Center for Biotechnol-
ogy Research (ICBR), along with appropriate sequencing
primers. Individual sequencing reads were assembled into
contigs using the Wisconsin package, version 10.3 (Accelrys
Inc., San Diego, CA) or Vector NTI version 8.0.
Marker rescue
A one-step marker rescue mapping of IBT-resistant vaccinia
virus mutants was performed as described by Condit et al.
(1991), with minor modifications. Briefly, confluent 60 mm
dishes of BSC40 cells were infected with Dts38, which serves
as a helper virus. Dishes were then co-transfected with genomic
wild type vaccinia virus DNA and a DNA fragment from the
IBT-resistant mutant and incubated at 37 °C in the presence of
IBT until 4 days post-infection. This helper virus-mediated
protocol employed two selections, temperature and IBT, and
thus resulted in a lower background than using wild type virus
for the infections. Rather than using cloned viral DNA for the
transfected IBT-resistant mutant DNA fragment, PCR products
were used. For use in preliminary mapping experiments, PCR
amplification was performed as described using a library of
primers designed and generously donated by Benjamin Luttge
and Richard Moyer to create 40 overlapping 5 kbp products that
collectively span the vaccinia genome (Luttge and Moyer,
2005). Once a 5 kbp PCR product was identified as containing
the IBT resistance locus, individual open reading frames in that
5 kbp region were amplified from genomic viral DNA and used
in a subsequent marker rescue experiment to map each mutant
to an individual gene.
RNA isolation
Confluent 60 mm dishes of BSC40 cells were infected with
wild type or mutant virus at a m.o.i. of 15 and incubated for 9 h
at 37 °C. The cells were washed with PBS containing 0.01%
BSA and 10 mM MgCl2, and total cellular RNA was then
isolated using the RNeasy RNA isolation kit (Qiagen) according
to the manufacturer's protocol. Two column elutions were each
performed with 50 μl RNase-free water. Measurement of ab-
sorbance at 260 nm was used to determine RNA concentration.
Riboprobes
Riboprobes specific for the 500 bp at the 5′ end of K2L,
A10L, and A18R mRNAs were transcribed from PCR products.
To do this, transcription templates were PCR amplified using a
forward primer complementary with the 5′ end of the open
reading frame (ORF) and a reverse primer complementary to a
region 500 bp downstream of the 5′ end of the ORF and tagged
with the sequence “CGATTTAGGTGACACTATAGAAGCG”
containing the bacteriophage SP6 promoter. (The essentialpromoter region is in italics, while two 5′ nucleotides and four
3′ nucleotides have been added to promote efficient transcrip-
tion.) Transcription from PCR products was performed with the
Ambion MAXIscript in vitro transcription system (Ambion,
Inc., Austin, TX).
Northern blotting
RNA samples were combined with RNA sample loading
buffer containing ethidium bromide to give a final concentration
of 20.6% formamide, 376 mM formaldehyde, and 0.4×MOPS
(1×MOPS=20 mM MOPS, 5 mM sodium acetate, 1 mM
EDTA, pH 7.0) and denatured by heating to 70 °C for 10 min.
Samples were then loaded onto a 1% agarose gel containing
2.2 M formaldehyde and 1×MOPS buffer. Gels were electro-
phoresed at 20 V for 16 h, during which time the 1×MOPS
running buffer was continuously recirculated using a peristaltic
pump. The RNA was partially hydrolyzed by soaking the gels
first in water and then in 0.05 N NaOH, each for 20 min. The
gels were then soaked in 20 × SSC (transfer buffer;
1×SSC=15 mM sodium citrate, 150 mM sodium chloride)
for 40 min prior to transfer to a GeneScreen neutral charge
membrane (PerkinElmer, Boston, MA). Membranes were pre-
hybridized at 55 °C in a hybridization oven (Labnet Interna-
tional, Inc., Woodbridge, NJ) for at least 2 h in buffer containing
50 mM Tris–HCl pH 7.5, 1 M NaCl, 50% formamide, 1% SDS,
0.1% sodium pyrophosphate, 10×Denhardt's reagent (0.2%
BSA, 0.2% polyvinylpyrolidone, 0.2% Ficoll), 10% dextran
sulfate, and 0.1 mg/ml salmon sperm DNA denatured by
heating to 95 °C for 10 min. Following pre-hybridization,
1×107 cpm fresh riboprobe was added to each blot and
incubated overnight at 55 °C. Blots were then quickly washed
once with 1×SSC containing 0.1% SDS at room temperature,
four times with 1×SSC containing 1% SDS at 65 °C, and
exposed to film.
Infected cell extracts for in vitro transcription
A549 cells were grown to confluency in 100 mm dishes
and infected with either wild type vaccinia virus strain WR
(Condit and Motyczka, 1981), DL1-3, DL2-4, DL3-2, DL4-
10, DL5-7, DL7-3, DL8-1, or DL10-7 at a multiplicity of
infection of 10 at 37 °C. The infected cells were incubated in
media containing 10 mM hydroxyurea, which inhibits
vaccinia virus DNA replication and promotes accumulation
of intermediate gene transcription factors. At 16 to 18 h post-
infection, cell extracts were prepared as described previously
(Condit et al., 1996a).
Templates for in vitro transcription
The pG8GU template used in the in vitro transcription
reaction has been previously described (Prins et al., 2004).
Briefly, the bead-bound pG8GU template contains 240 bp of
plasmid DNA upstream of the vaccinia virus intermediate G8
promoter, followed by a 37 bp G-less cassette, a 40 bp T-less
cassette, a stretch of 9 T's, and another 42 bp of plasmid DNA
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conjugated Dynabeads M280 (Dynal), as described previously
(Lackner and Condit, 2000).
In vitro transcription elongation assay
The in vitro transcription elongation assay was performed as
described previously (Prins et al., 2004). Vaccinia virus infected
cells extracts (15 μg) are combined with template DNA and
transcription buffer for a 25 μl reaction containing 5 mM
MgCl2, 25 mM HEPES pH 7.4, 1.6 mM DTT, 80 mM KOAc,
1 mM ATP, 1 mM UTP, 1 μM CTP, 200 μM 3′-O-MethylGTP,
and 6 μCi [alpha-32P]-CTP (3000 Ci/mmol stock, Perkin
Elmer). Reactions were incubated for 20 min at 30 °C to form
“pulse complexes”. This allows transcription elongation to
proceed to the end of the 37 bp G-less cassette where the 3′-O-
MethylGTP is incorporated, causing transcriptional arrest. The
paramagnetic bead-bound ternary transcription elongation
complexes were isolated on a magnet, and were then washed
3 times in 1–1.5 reaction volumes of low-salt wash buffer
containing 5 mMMgCl2, 25 mM HEPES pH 7.4, 1.6 mM DTT,
80 mM KOAc, 200 μg/μl BSA, and 7.5% glycerol. Washed
transcription complexes were resuspended in transcription
buffer containing 5 mM MgCl2, 25 mM HEPES pH 7.4,
1.6 mM DTT, 80 mM KOAc, and 20 units RNAsin (Promega).
The complexes were then chased in the presence of 1 mM ATP,
1 mM CTP, 1 mM GTP and differing levels of UTP at 30 °C for
5 or 30 min. Reactions were incubated at 37 °C for 30 min with
175 μl of PK mix (114 mM Tris–HCl pH 7.5, 14 mM EDTA,
171 mM NaCl, and 1.1% SDS, 230 μg/ml Proteins K, 800 μg
glycogen) and nucleic acids were extracted with 175 μl of
phenol/chloroform and then precipitated by adding 290 μl 10 M
NH4OAc and 400 μl isopropyl alcohol and incubating at room
temperature for 30 min. The precipitated DNAwas pelleted by
centrifuging samples for 20 min and removing the supernatant.
Pellets were washed with cold 70% ethanol and resuspended in
10 μl of formamide loading buffer. Samples were heated at
95 °C for 2 min and run on a 10% 8 M urea-PAGE. Gels were
fixed, dried and exposed to a phosphor screen (Molecular
Dynamics) that was analyzed using a Storm phosphorimager
(Molecular Dynamics) and the ImageQuant (Molecular
Dynamics) program.
Homology modeling
Homology models of the rpo147 and rpo132 proteins were
constructed using ClustalW, Swiss-PdbViewer, version 3.7,
and the Swiss-Model homology modeling server (http://
swissmodel.expasy.org). An amino acid sequence alignment
of rpo147 and S. cerevisiae rpb1 (Protein Data Bank codes
1i6hA and 1nikA) or rpo132 and S. cerevisiae rpb2 (Protein
Data Bank codes 1i6hB and 1nikB) was constructed using
ClustalW and used by Swiss-PdbViewer to generate a
structural alignment. The structural alignment was edited by
hand and submitted to the SwissModel as an “optimize”
request for construction of a homology model. The Swiss-
PdbViewer was used to export views of the model as Mega-Pov scenes that were rendered using POV-Ray (http://www.
pov-ray.org) version 3.5 for Linux.
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